For the Inventor, By the Inventor

Enter inventor name

Morrisville, PA, United States of America

David Brent Rawlins

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 4

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.3

ph-index = 6

Forward Citations = 175(Granted Patents)

Location History:

Morrisville, NJ (US) (2015)
Morrisville, PA (US) (2000 - 2018)

Company Filing History:

Lexicon Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Years Active: 2000-2018

Loading Chart...

Loading Chart...

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106569 - Inhibitors of sodium glucose transporter 1 for constipation (2018-10-23),

2. 9688710 - Inhibitors of sodium glucose cotransporter 1 (2017-06-27),

3. 9365602 - Sodium glucose co-transporter inhibitors and methods of their use (2016-06-14),

4. 9200025 - Inhibitors of sodium glucose cotransporter 1 (2015-12-01),

5. 8507672 - Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors (2013-08-13),

6. 8476413 - Sulfanyl-tetrahydropyran-based compounds and methods of their use (2013-07-02),

7. 8450332 - LIMK2 inhibitors, compositions comprising them, and methods of their use (2013-05-28),

8. 8193202 - LIMK2 inhibitors, compositions comprising them, and methods of their use (2012-06-05),

9. 7846945 - Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use (2010-12-07),

10. 7781577 - Inhibitors of sodium glucose co-transporter 2 and methods of their use (2010-08-24),

11. 7423043 - [object Object] (2008-09-09),

12. 6809102 - Cyano-substituted dihydropyrimidine compounds and their use to treat diseases (2004-10-26),

13. 6720347 - Carbon substituted aminothiazole inhibitors of cyclin dependent kinases (2004-04-13),

14. 6649606 - Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity (2003-11-18),

15. 6521759 - Aminothiazole inhibitors of cyclin dependent kinases (2003-02-18),

Title: David Brent Rawlins – Innovator in Pharmaceutical Technologies

Introduction

David Brent Rawlins, an accomplished inventor based in Morrisville, PA, is credited with 19 patents to his name. His contributions primarily focus on pharmaceutical innovations, particularly involving glucose transport and diabetes treatments. His work reflects a commitment to addressing critical health issues through inventive solutions.

Latest Patents

Among his latest patents are notable inventions related to inhibitors of sodium glucose transporter 1 (SGLT1). These patents encompass compositions designed to treat various diseases and disorders, including diabetes, through the modulation of SGLT1. The specific compounds he developed are defined precisely with various substituents, showcasing his meticulous approach to pharmaceutical formulation.

Career Highlights

Throughout his career, David Brent Rawlins has held significant roles in leading pharmaceutical companies, including Lexicon Pharmaceuticals, Inc. and Bristol-Myers Squibb Company. His tenure at these organizations has allowed him to influence drug development and advance therapies that improve patients' lives.

Collaborations

David has collaborated with notable individuals in the field, such as Bryce Alden Harrison and Ross Mabon. These partnerships have fostered a rich environment for innovation and creativity, resulting in numerous advancements in the pharmaceutical sector.

Conclusion

David Brent Rawlins stands out as a key figure in pharmaceutical innovation. His extensive portfolio of patents, focus on SGLT1 inhibitors, and collaborative spirit emphasize his dedication to enhancing medical treatments. As he continues to contribute to the field, his work promises to leave a lasting impact on healthcare and patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…